Cargando…
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
PURPOSE OF REVIEW: Apolipoprotein C-III (apoC-III) is known to inhibit lipoprotein lipase (LPL) and function as an important regulator of triglyceride metabolism. In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease. This review summariz...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527792/ https://www.ncbi.nlm.nih.gov/pubmed/31111320 http://dx.doi.org/10.1007/s11883-019-0791-9 |